Agomab Therapeutics has priced its initial public offering at 16 dollars per American Depositary Share (ADS), raising expected gross proceeds of approximately 200 million dollars before underwriting discounts and expenses.
The Belgian clinical-stage biopharmaceutical company is offering 12.5 million ADSs, each representing one common share.
The shares are set to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker AGMB, with the transaction expected to close on February 9, subject to customary conditions.
Agomab has also granted underwriters a 30-day option to purchase up to 1.875 million additional ADSs at the IPO price.
J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen are acting as joint book-running managers for the offering.
Headquartered in Antwerp, Agomab is focused on developing disease-modifying therapies for immunology and inflammatory disorders, with an initial emphasis on chronic fibrotic diseases that carry significant unmet medical need.
Its pipeline targets established biological pathways using validated modalities, with the goal of improving efficacy while limiting systemic toxicities.
The registration statement for the IPO was declared effective by the U.S. Securities and Exchange Commission on January 30, 2026.
The offering is being made solely by means of a prospectus and is not available for public distribution outside the United States where regulatory approvals would be required.
